Kappa Bioscience strengthens its Scientific and Medical Advisory Board with newly appointed member

17-Aug-2022

Kappa Bioscience, the leading manufacturer of vitamin K2 under the brand name K2VITAL, has announced the appointment of Dr John E. Repine MD as the newest member of its “Blue Ribbon” Scientific and Medical Advisory Board

Kappa Bioscience strengthens its Scientific and Medical Advisory Board with newly appointed member

Following the formation of the Board under the guidance of Bernie Landes MBA, President of Nutritional Products Consulting Group LLC, now Executive Director, this new appointment solidifies the company's strategic commitment to support and expand the scientific knowledge base for vitamin K2.

As well as supporting the Board, Dr Repine will continue his duties as the Waring Endowed Professor of Medicine, Pediatrics, and Surgery, the Webb-Waring Center Director, and the Associate Dean for Student Advocacy at the University of Colorado School of Medicine in Aurora, Colorado.

Having graduated from the University of Minnesota School of Medicine and then completed clinical training in Internal, Pulmonary, and Critical Care Medicine, Dr Repine brings a wealth of scientific research and expertise to the Board – with specialisms in inflammation, oxidative stress, neutrophils, macrophages, electromagnetic fields, and Acute Respiratory Distress Syndrome (ARDS).

Dr Repine said: “I'm honoured to have been invited to join this esteemed group of top-class experts. I look forward to supporting the Kappa Bioscience team to expand awareness of vitamin K2 and uncover the full scope of health benefits it can offer."

The Scientific and Medical Advisory Board was set up to support Kappa's unique commitment to growing awareness of the rapidly expanding range of benefits associated with all-trans vitamin K2 in the form of Menaquinone 7 (MK-7).

As an active member of the Board, Dr Repine will join an impressive line-up of world authorities in relevant fields of science – including cardiology, immunology, kinesiology, and molecular nutrition – to set a new standard for the scientific support and advancement of emerging nutritional compounds.

Egil Greve, Kappa Bioscience President and CEO, comments: “We’re excited to welcome Dr Repine as the newest member of our Advisory Board. With his extensive scientific expertise, combined with our highly qualified internal science team, we aim to expand the scope of scientific research into K2 and raise further awareness about its role in maintaining health.”

Sign up for your free email newsletter

Dominik Mattern, EVP Marketing, concludes: “Kappa Bioscience has always been a frontrunner in K2. As we continue to grow and expand our Scientific and Medical Advisory Board with the addition of experts like Dr Repine, we aim to keep delving deeper in our exploration of the potential health benefits this vitamin can bring, and to share it with our customers all over the world.”

Companies